Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
ASCO-GU – some backing for Pfizer's EZH2 plan
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
SpringWorks is in the air for Merck KGaA
The deal isn’t done, but would be Merck’s biggest oncology buy.
Kura’s Komet fizzles
The company heralds a pivotal win with its menin inhibitor, but investors want to see data.
